"CREB-Binding Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the p300-CBP transcription factor family that was initially identified as a binding partner for CAMP RESPONSE ELEMENT-BINDING PROTEIN. Mutations in CREB-binding protein are associated with RUBINSTEIN-TAYBI SYNDROME.
| Descriptor ID |
D050882
|
| MeSH Number(s) |
D08.811.913.050.134.415.500.575.249 D12.776.930.680.300
|
| Concept/Terms |
CREB-Binding Protein- CREB-Binding Protein
- CREB Binding Protein
- Nuclear Protein CBP
- CBP, Nuclear Protein
- Phospho-CREB-Binding Protein
- Phospho CREB Binding Protein
|
Below are MeSH descriptors whose meaning is more general than "CREB-Binding Protein".
Below are MeSH descriptors whose meaning is more specific than "CREB-Binding Protein".
This graph shows the total number of publications written about "CREB-Binding Protein" by people in this website by year, and whether "CREB-Binding Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 4 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 3 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CREB-Binding Protein" by people in Profiles.
-
CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer. JCI Insight. 2024 Sep 17; 9(20).
-
Near-Haploid B-Cell Acute Lymphoblastic Leukemia in a Patient with Rubinstein-Taybi Syndrome. Pediatr Hematol Oncol. 2022 Nov; 39(8):747-754.
-
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
-
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia. 2020 12; 34(12):3269-3285.
-
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500.
-
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459.
-
E2F1 acetylation directs p300/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair. Nat Commun. 2019 10 30; 10(1):4951.
-
Genotype-phenotype specificity in Menke-Hennekam syndrome caused by missense variants in exon 30 or 31 of CREBBP. Am J Med Genet A. 2019 06; 179(6):1058-1062.
-
Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. Ann Hematol. 2019 May; 98(5):1149-1157.
-
The circular RNome of primary breast cancer. Genome Res. 2019 03; 29(3):356-366.